Adrenomed
Latest round
- Series E
Last raised
- Nov 2020
Total raised
- $60M
Investors
- 2
About Adrenomed
Founded in 2009, Adrenomed AG is based in Hennigsdorf, Germany. The company specializes in developing monoclonal antibodies, with its lead product being Enibarcimab, aimed at addressing severe vascular complications.5 million from HBM Partners.Adrenomed AG specializes in developing innovative biopharmaceuticals aimed at restoring vascular integrity in critically ill patients. Its core product, Enibarcimab (formerly known as Adrecizumab), is a first-in-class monoclonal antibody designed to target the vasoprotective peptide Adrenomedullin. This treatment addresses life-threatening conditions such as septic shock, where loss of vascular integrity leads to severe complications including increased vascular leakage and organ dysfunction. By leveraging a biomarker-guided approach using two specific biomarkers—bio-ADM and DPP3—Adrenomed enables healthcare providers to identify patients who are most likely to benefit from therapy with Enibarcimab.Adrenomed AG operates within a clinical-stage biopharmaceutical model, focusing on partnerships with healthcare institutions and clinical trial networks to advance its product development. The company generates revenue through strategic collaborations and potentially through the future commercialization of Enibarcimab, which is currently undergoing pivotal clinical trials including a Phase II proof-of-concept study. In this model, transactions typically involve agreements with hospitals and research institutions for the clinical deployment of their products, as well as licensing agreements for potential future sales. The company aims to expand its product offerings and enter new markets, with a focus on regions such as Belgium, France, Germany, and the Netherlands, where it currently evaluates its products.
Who invested in Adrenomed
2 investors across 5 rounds
See all investors in Adrenomed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adrenomed
Who invested in Adrenomed?
Adrenomed has 2 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adrenomed raised?
Adrenomed has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Adrenomed last raise money?
Adrenomed's most recent round on record is a Series E, in Nov 2020.
What does Adrenomed do?
Founded in 2009, Adrenomed AG is based in Hennigsdorf, Germany.
Where is Adrenomed headquartered?
Adrenomed is headquartered in Hennigsdorf, Germany.
Which VCs invest in companies like Adrenomed?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Adrenomed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Adrenomed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.